Loading
CHISEL is the randomised trial that proved stereotactic radiotherapy beats conventional radiotherapy for early lung cancer in patients who cannot have surgery, with better local control and longer survival.
CHISEL randomised 101 patients with peripheral stage I non-small-cell lung cancer unfit for surgery to stereotactic ablative radiotherapy (54 Gy in three or 48 Gy in four fractions) or conventional radiotherapy (66 Gy in 33 or 50 Gy in 20). Local failure was less frequent with stereotactic treatment (hazard ratio 0.32) and overall survival was longer, median 5 years versus 3 years, with similar toxicity (Ball and colleagues, Lancet Oncology 2019).
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
101 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Local treatment failure (freedom from local failure was the primary endpoint)primary | SABR | 66 | 14% | 0.32 (0.13 to 0.77) | 0.0077 | link |
| Standard radiotherapy | 35 | 31% |
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiation-wave2.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiation-wave2.
Shares STARS and ROSEL pooled analysis, Resectable stage I to III non-small-cell lung cancer, Lung cancer (all types), Non-small-cell lung cancer.
Shares STARS and ROSEL pooled analysis, Resectable stage I to III non-small-cell lung cancer, Lung cancer (all types).
Shares TROG Cancer Research, SBRT / SABR (stereotactic radiotherapy).